Baird Rates IQVIA (IQV) buy, $249 Price Target

Baird maintains its buy rating on IQVIA Holdings with a $249 price target, a 28.87% upside from the current price.

By EarningsIQ Research Desk · Published Jul 1, 2026, 8:00 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Baird rated IQVIA Holdings Inc. ($IQV) "buy" with a $249 price target on July 1, 2026.

Since the rating, $IQV is up 0.3% after 1 week, up 15.7% after 1 month and up 31.4% to date (from the $203.20 close on Jul 1, 2026).

IQV IQVIA Holdings Inc.

$266.90 +18.43% year to date

Daily close · Oct 16, 2026

Key Points

Baird reiterated its buy rating on IQVIA Holdings Inc. (NYSE:IQV) with a price target of $249 as of July 1, 2026.
Baird's $249 price target implies 28.87% upside from IQVIA Holdings Inc.'s ($IQV) current $193.22 share price.
On Wednesday, IQVIA shares were trading around $193.22, with a market cap of approximately $32.25 billion.
Other analysts like Morgan Stanley and TD Cowen have varied ratings, with targets ranging from $200 to $221.

Get $IQV trade alerts by text

We text you when insiders, Congress or big funds trade $IQV. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated IQVIA Holdings Inc. alert may contain errors. Disclosures

On July 1, 2026, Baird reiterated its buy rating on IQVIA Holdings Inc. (NYSE:IQV), setting a price target of $249. This reflects continued confidence in the company by analyst Eric Coldwell. IQVIA shares were trading near $193.22 on Wednesday.

Analyst rating track record

Baird vs. the S&P 500

YTD return +11.58% hypothetical

All-time return +17.20% S&P 500 +29.66%

vs. S&P 500 -12.46% behind the index

Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.

IQVIA Holdings Inc. Stock Down 27.5%

IQVIA Holdings Inc. is a major player in the healthcare sector, specifically in diagnostics and research. The company has a market capitalization of about $32.25 billion. It trades on the NYSE under the ticker IQV. The stock has a P/E ratio of 24.0 and a forward P/E of 13.6, indicating expectations for growth. The beta of 1.215 suggests the stock is somewhat more volatile than the market. Over the past 52 weeks, the stock has ranged from $154.50 to $247.05, with a 50-day moving average of $174.50 and a 200-day moving average of $195.21.

12-month forecast

$IQV price target

IQVIA Holdings Inc. daily closes and this analyst's $249 target. Not advice.

Recent Earnings

IQVIA reported revenue of $16.63 billion, with a growth rate of 8.4%. The company achieved an EPS of $8.06, reflecting a net margin of 8.3% and a return on equity of 22.5%. The next earnings report is expected on July 21, 2026.

Insider Buying and Selling at IQVIA Holdings Inc.

Several insiders made purchases in May 2026. John Danhakl bought 185 shares at an average price of $178.64, while Colleen Goggins acquired 214 shares at the same price. Jim Fasano also made two purchases, one for 228 shares at $178.64 and another for 1,571 shares at $160.68. These transactions were not part of any pre-planned trading program.

Analysts Set New Price Targets

On July 1, 2026, Baird maintained its buy rating for IQVIA with a target price of $249. Morgan Stanley had earlier downgraded the stock to hold with a $200 target on June 17, 2026. Meanwhile, TD Cowen upgraded its rating to buy with a target of $213, showing a range of perspectives on the stock's potential.

About IQVIA Holdings

IQVIA Holdings Inc. provides a range of services to the life sciences industry, including clinical research, commercial insights, and healthcare intelligence. Based in Durham, North Carolina, the company operates through three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Led by CEO Ari Bousbib, IQVIA employs around 93,000 people worldwide, delivering services that help improve healthcare outcomes.

Bottom Line

Baird's reiteration of a buy rating with a $249 target highlights continued confidence in IQVIA's growth prospects. Investors often track such analyst ratings to gauge market sentiment. It's important to note that ratings and targets are based on projections and can change over time.